STRATA Skin Sciences Hits 52-Week Low of $1.33 Amid Financial Struggles

STRATA Skin Sciences, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.33 on November 14, 2025. This marks a significant decline, reflecting a 54.05% drop in its performance over the past year, contrasting sharply with the S&P 500's gain of 13.19% during the same period.
The company's market capitalization stands at approximately USD 9 million, and it has been grappling with substantial operating losses. STRATA's financial metrics reveal a challenging landscape, with a return on equity of -767.90% and a debt-to-equity ratio of 9.61, indicating a high level of leverage. The stock's price-to-book ratio is 9.17, suggesting that the market values the company significantly higher than its book value.

Despite the recent price movement, STRATA has struggled with weak long-term growth, as evidenced by an annual decline in operating profit of -33.37% over the last five years. The company's ability to service its debt remains a concern, highlighted by a poor EBIT to interest ratio of -4.08. Overall, STRATA Skin Sciences, Inc. continues to face a challenging financial environment as it navigates these difficulties.